NCT01438593

Study of Purified Umbilical Cord Blood CD34+ Stem Cell on Chronic Ischemic Stroke

An Exploratory Clinical Trial to Assess Treatment of Chronic Ischemic Stroke With Brain Transplants of Purified CD34+ Umbilical Cord Blood Stem Cells

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (estimated)
• Sponsor: China Medical University Hospital · Academic / Other
• Sex: All
• Age: 35 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine the safety and possible effectiveness of brain transplants of CD34+ stem cells obtained from umbilical cord blood (UCB) to treat stroke.

Detailed description

The study will use CD34+ cells (a special kind of cell that is believed to be a stem cell) isolated from UCB (blood obtained at birth from the umbilical cord blood of babies). StemCyte, a leading accredited UCB banking company with branches in the United States and Taiwan, will provide the units of UCB that match at least 5 out of 6 HLA (human leukocyte antigens) for transplantation. The HLA-matching is the same as that used to match cells and organs for transplantation so that the body does not reject the cells. We will isolate CD34 cells from these units, purified them, suspend the cells in solution (1 ml containing 2-8 million cells), and inject the cells into brain around the site damaged by the stroke

Conditions

• Ischemic Stroke
• Ischaemic Cerebral Infarction
• Infarction, Middle Cerebral Artery
• Ischemia
• Brain Ischemia

Interventions

Type	Name	Description
PROCEDURE	Intercerebral implantation of allogenic CD34+ stem cell	Each patient will receive brain implant of approximately 5 million allogenic Umbilical cord blood CD34+ Stem Cell

Timeline

• Start date: 2013-01-01
• Primary completion: 2013-12-01
• Completion: 2013-12-01
• First posted: 2011-09-22
• Last updated: 2012-08-02

Locations

1 site across 1 country: Taiwan